We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.76 | -1.91% | 39.01 | 32,783 | 11:03:52 |
From Jul 2019 to Jul 2024
By Maryam Cockar
GlaxoSmithKline PLC (GSK.LN) said Wednesday that its subsidiary has reported positive results in its first phase 3 study for an injectable two-drug regimen for the treatment of HIV.
GSK said ViiV Healthcare Ltd.'s study showed similar efficacy of a once-a-month, injectable two-drug regimen of cabotegravir and rilpivirine drugs compared with a standard daily, oral three-drug regimen.
If the two-drug regimen is approved it would give people living with HIV one month between each dose of antiretroviral therapy, changing HIV treatment from 365 doses days a year to 12 doses, John Pottage, chief scientific and medical officer of ViiV Healthcare, said.
ViiV Healthcare, a specialist HIV company, is majority owned by GSK with Pfizer Inc. (PFE) and Shionogi & Co. Ltd. (4507.TO).
Write to Maryam Cockar at maryam.cockar@dowjones.com
(END) Dow Jones Newswires
August 15, 2018 02:34 ET (06:34 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
